Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OGA | O60502 | 19/20 | 1.00 |
| ▸ | HEXB | P07686 | 6/20 | 0.77 |
| ▸ | HOGA1 | Q86XE5 | 1/20 | 0.67 |
| ▸ | HEXA | P06865 | 1/20 | 0.66 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1899664 | 1.00 | OGA (1.00) | OGAHEXBHOGA1HEXA | |
| SCHEMBL14360249 | 1.00 | OGA (1.00) | OGAHEXBHOGA1HEXA | |
| SCHEMBL14360524 | 1.00 | OGA (1.00) | OGAHEXBHOGA1HEXA | |
| SCHEMBL4559749 | 1.00 | OGA (1.00) | OGAHEXBHOGA1HEXA | |
| SCHEMBL14359898 | 1.00 | OGA (1.00) | OGAHEXBHOGA1HEXA | |
| SCHEMBL14362101 | 1.00 | OGA (1.00) | OGAHEXBHOGA1HEXA | |
| SCHEMBL4538597 | 0.88 | OGA (0.79) | OGAHEXBHOGA1 | |
| SCHEMBL4562644 | 0.88 | OGA (0.78) | OGAHEXBHOGA1 | |
| SCHEMBL4562643 | 0.88 | OGA (0.78) | OGAHEXBHOGA1 | |
| SCHEMBL4536649 | 0.88 | OGA (0.78) | OGAHEXBHOGA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2322529-B1 | Selective glycosidase inhibitors and uses thereof | UNIV FRASER SIMON (CA) | 2017-12-06 | — | — | EP | disclosed |
| EP-2322529-B1 | Selective glycosidase inhibitors and uses thereof | UNIV FRASER SIMON (CA) | 2017-12-06 | — | — | EP | disclosed |
| US-8962664-B2 | Selective glycosidase inhibitors and uses thereof | SIMON FRASER UNIVERSITY (CA) | 2015-02-24 | — | — | US | disclosed |
| US-8962664-B2 | Selective glycosidase inhibitors and uses thereof | SIMON FRASER UNIVERSITY (CA) | 2015-02-24 | — | — | US | disclosed |
| US-8334310-B2 | Selective glycosidase inhibitors and uses thereof | SIMON FRASER UNIVERSITY (CA) | 2012-12-18 | — | — | US | disclosed |
| US-8334310-B2 | Selective glycosidase inhibitors and uses thereof | SIMON FRASER UNIVERSITY (CA) | 2012-12-18 | — | — | US | disclosed |
| US-20120316207-A1 | SELECTIVE GLYCOSIDASE INHIBITORS AND USES THEREOF | SIMON FRASER UNIVERSITY (CA) | 2012-12-13 | — | — | US | disclosed |
| US-20120316207-A1 | SELECTIVE GLYCOSIDASE INHIBITORS AND USES THEREOF | SIMON FRASER UNIVERSITY (CA) | 2012-12-13 | — | — | US | disclosed |
| EP-2322529-A1 | Selective glycosidase inhibitors and uses thereof | Simon Fraser University (CA) | 2011-05-18 | — | — | EP | disclosed |
| EP-2322529-A1 | Selective glycosidase inhibitors and uses thereof | Simon Fraser University (CA) | 2011-05-18 | — | — | EP | disclosed |
| US-20100016386-A1 | SELECTIVE GLYCOSIDASE INHIBITORS AND USES THEREOF | SIMON FRASER UNIVERSITY (CA) | 2010-01-21 | — | — | US | disclosed |
| US-20100016386-A1 | SELECTIVE GLYCOSIDASE INHIBITORS AND USES THEREOF | SIMON FRASER UNIVERSITY (CA) | 2010-01-21 | — | — | US | disclosed |
| EP-2057171-A1 | SELECTIVE GLYCOSIDASE INHIBITORS AND USES THEREOF | Simon Fraser University (CA) | 2009-05-13 | — | — | EP | disclosed |
| WO-2008025170-A1 | SELECTIVE GLYCOSIDASE INHIBITORS AND USES THEREOF | SIMON FRASER UNIVERSITY (CA) | 2008-03-06 | — | — | WO | disclosed |
| WO-2008025170-A1 | SELECTIVE GLYCOSIDASE INHIBITORS AND USES THEREOF | SIMON FRASER UNIVERSITY (CA) | 2008-03-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100016386-A1 | SELECTIVE GLYCOSIDASE INHIBITORS AND USES THEREOF | ENGASE, OGA, GALE | OGA 2/4885HEXB 37/4885HOGA1 324/4885 |
| US-20120316207-A1 | SELECTIVE GLYCOSIDASE INHIBITORS AND USES THEREOF | ENGASE, OGA, GALE | OGA 2/4885HEXB 40/4885HOGA1 260/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.